U.S. Drug of Abuse (DoA) Testing Market - Analysis and Forecast To 2024, Waters Corporation, Abbott Laboratories, Psychemedics Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche AG.

Industry Overview
The U.S. drug of abuse (DoA) testing market is expected to grow at a CAGR of 9.7% during the forecast period with its market size predicted to reach USD 3.6 billion by 2024. The U.S. DoA testing market is primarily driven by the stringent laws and regulations, government initiatives, and increasing awareness against drug abuse and development of advanced drug test equipment. The testing for drug abuse requires products such as immunoassay analyzers, chromatography instruments, breath analyzers, rapid test kits, and assay kits & reagents.

Download Free Report Sample at: https://www.vynzresearch.com/healthcare/us-drug-of-abuse-testing-market/request-sample

Growth Drivers
The stringent laws and regulations, government initiatives to curb drug abuse, and increasing awareness against drug abuse and development of advanced drug test equipment are the primary growth drivers for the U.S. DoA testing industry. The substance misuse and its addiction of opioids such as morphine and heroin have been a serious concern for the U.S. government as it affects the socio-economic welfare and public healthcare. The National Institute on Drug Abuse reported that an estimated 1.9 million people in the United States suffered from substance use disorders related to prescription opioid pain medicines in 2013 and 517,000 suffered from a heroin use disorder.

The government in the country is promoting educational initiatives to be delivered in school and communities, supporting prescription drug monitoring programs, implementing overdose education and naloxone distribution programs, and aggressive law enforcement efforts. The government is also supporting the investment for research and development for pain management and next-generation analgesics. This is anticipated fuel the market for DoA testing in the U.S.

Read More: https://www.vynzresearch.com/healthcare/us-drug-of-abuse-testing-market

Challenges
The legalization of certain drugs and inability to detect low dose modified drugs are the key challenges faced by the U.S. DoA testing industry.

Competitive Insight
Some of the key players operating in the U.S. DoA testing market are Siemens AG, Danaher Corporation, Merck KGaA, Laboratory Corporation of America Holdings, Express Diagnostics Int'l, Inc., Quest Diagnostics Inc., Waters Corporation, Abbott Laboratories, Psychemedics Corporation, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., and F. Hoffmann-La Roche AG.

Contact
Manager: Client Care
Toll-Free: 18882533960
Email: kundan@vynzresearch.com
Website: www.vynzresearch.com

Who We Are
VynZ Research is a global market research firm offering research, analytics, and consulting services on business strategies. We have a recognized trajectory record and our research database is used by many renowned companies and institutions in the world to strategize and revolutionize business opportunities. The company focuses on providing valuable insights on various technology verticals such as Chemicals, Automotive, Transportation, Energy, Consumer Durables, Healthcare, ICT and other emerging technologies.

This release was published on openPR.